For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
HIV Single-tablet Regimens – “The Future is Now”
with Dr. Harold Dion and Dr. Marianne Harris
- HIV single-tablet regimens (STRs) are simple, safe, and promote better adherence
- 70% to 80% of patients in STR clinical trials reached the target for viral load suppression in two to three years
- TAF is a new formulation of tenofovir that is easier to coformulate and leads to fewer toxicity problems
- Numerous promising clinical studies will likely result in interesting STR options for patients
HIV Single-tablet Regimens
Dr. Marianne Harris, Clinical Research Advisor for the B.C. Centre for Excellence in HIV/AIDS, discusses with Dr. Dion the highlights of her presentation on single-tablet HIV regimens, entitled “The Future is Now.”
STRs offer many advantages for patients. They are safe and simple, they result in better adherence, and, at least in theory, they lead to a better virological outcome.
A number of clinical trials now underway will likely offer very interesting options for patients, particularly those who cannot take tenofovir, which has been the backbone of all STRs until now.
TAF, a new form of tenofovir that is easier to co-formulate and leads to fewer side effects, is currently being studied. Furthermore, two pharmaceutical companies have joined forces to study a potential new nucleoside sparing regimen that involves combining two existing drugs, dolutegravir and rilpivirine.
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Harold Dion, MD, CCMF, FCMF has a financial interest/relationship or affiliation in the form of:
Speakers bureau for: BMS, Gilead, Janssen, ViiV Healthcare
Marianne Harris, MD, CFPC has a financial interest/relationship or affiliation in the form of:
Grants/Research Support: AbbVie, Bristol-Myers Squibb Canada, Gilead Sciences Canada Inc., Janssen Inc., Merck Canada Inc., ViiV Healthcare, Vertex Pharmaceuticals Inc.
Speakers Bureau/Honoraria: AbbVie, Bristol-Myers Squibb Canada, Gilead Sciences Canada Inc., Janssen Inc., Merck Canada Inc., ViiV Healthcare
Consulting Fees: AbbVie, Bristol-Myers Squibb Canada, Gilead Sciences Canada Inc., Janssen Inc., Merck Canada Inc., ViiV Healthcare
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.